Edwards Lifesciences' (EW) CEO Mike Mussallem on Q2 2020 Results - Earnings Call Transcript

Edwards Lifesciences Corp. (NYSE:EW) Q2 2020 Earnings Conference Call July 23, 2020 5:00 PM ET

Company Participants

Mark Wilterding – Vice President-Investor Relations
Mike Mussallem – Chairman and Chief Executive Officer
Scott Ullem – Chief Financial Officer

Conference Call Participants

Josh Jennings – Cowen and Company
David Lewis – Morgan Stanley
Matt Miksic – Credit Suisse
Bob Hopkins – Bank of America
Robbie Marcus – JPMorgan
Larry Biegelsen – Wells Fargo
Matt Taylor – UBS
Raj Denhoy – Jefferies
Chris Pasquale – Guggenheim
Vijay Kumar – Evercore ISI
Pito Chickering – Deutsche Bank
Joanne Wuensch – Citi
Rick Wise – Stifel

Operator

Greetings, and welcome to the Edwards Lifescience Corporation Second Quarter 2020 Results Conference Call and Webcast. [Operator Instructions] Please note that this conference is being recorded.

I will now turn the conference over to our host, Mark Wilterding, Vice President of Investor Relations. Thank you. You may begin.

Mark Wilterding

Thanks, Diego. Good afternoon, everyone, and thank you for joining us. With me on today’s call are Mike Mussallem, Chairman and Chief Executive Officer; and Scott Ullem, Chief Financial Officer. Just after the close of regular trading, Edwards Lifesciences released second quarter 2020 financial results. During today’s call, management will discuss those results included in the press release and accompanying financial statements and then use the remaining time for Q&A.

Please note that management will be making forward-looking statements that are based on estimates, assumptions and projections. These statements include, but aren’t limited to, financial guidance and expectations for longer-term growth opportunities, regulatory approvals, clinical trials, litigation, reimbursement, competitive matters and foreign currency fluctuations. These statements speak only as of the date on which they were made, and Edwards does not undertake any obligation to update them after today. Additionally, the statements involve risks and uncertainties, including, but not limited to, those associated with COVID-19 pandemic that could cause actual results to differ materially. Information